Clinical Trial Costs and Phases: From Safety Testing to Market Approval

Clinical trials are the scientific engine behind nearly every new innovative therapy for chronic conditions including autoimmune, genetic, and neurological disorders, with drug development taking 10 to 15 years from discovery to approval for clinical use and costing anywhere between $1 billion to $2 billion. These rigorous studies are especially important for developing treatments for rare conditions that have historically received less research attention, and without them, life-saving discoveries made in laboratories would never reach those who are diagnosed with these diseases.

There are four phases of a clinical trial, with each one getting progressively more expensive than the last, especially as studies expand in size, complexity, and regulatory oversight. Phase I clinical trials are the first time a new drug or therapy is tested in humans, concentrating on safety including how the body tolerates a new drug, what side effects occur and which doses are safe. Researchers study how the drug is absorbed, distributed, metabolized and excreted, and how it interacts with its target, serving as the risk filter for the entire development pipeline.

Phase II begins to evaluate the efficacy of a possible new treatment in larger groups of people, while Phase III rigorously tests a new treatment in larger groups of people against the standard of care. Phase IV evaluates efficacy and safety in real-world populations through post-marketing surveillance.

Clinical research is highly regulated and closely monitored by global regulatory bodies such as the U.S. Food and Drug Administration, and meeting those standards requires extensive infrastructure including trained research staff with salaries ranging from $55,000 to $190,000 depending on the position. The cost of lab tests and imaging scans is trickier to calculate, with earlier trial phases focusing more heavily on such biometric data, and costs also depend on the disease area being studied—conditions that require repeat MRI or CAT scans can easily skyrocket costs.

Data storage isn't cheap either, as the amount and complexity of data required to establish safety and efficacy can vary by indication, type of data being collected, number of assessments, and time points required. Major challenges in clinical trials include ethical compliance, participant recruitment, and ensuring diversity and representativeness in trial populations.

To address these challenges, innovative technologies such as artificial intelligence, big data analytics, and digital health tools are transforming trial design and implementation, enhancing efficiency and data quality. Emerging therapies including gene therapy and immunotherapy are reshaping trial design requirements, while regulatory harmonization and global collaboration are growing in importance.

Illinois currently faces a shortage of Phase I clinical trial facilities, requiring many bioscience companies to conduct early-stage research outside the state. It is estimated that Illinois bioscience companies undertake more than 50 Phase I trials annually. With the exception of cancer and some other life-threatening diseases, most Phase I trials are performed in healthy volunteers.